Zymeworks Inc. Annual Report - Your 2023 Performance Snapshot

Unlock the key insights from Zymeworks Inc.'s 2023 annual report. This guide cuts through the jargon, offering a clear snapshot of the company's performance, financial health, and future prospects for the fiscal year ended December 31, 2023.

1. What Zymeworks Does and How It Performed in 2023

Zymeworks, a clinical-stage biotechnology company, develops innovative, antibody-based therapeutics targeting difficult-to-treat cancers. The company uses its proprietary Azymetric™ and Zymelink™ platforms to create bispecific antibodies and antibody-drug conjugates (ADCs). Unlike many biotech firms, Zymeworks primarily funds its research and development through strategic collaborations with major pharmaceutical companies. Key partners include Jazz Pharmaceuticals, Johnson & Johnson, GSK, Bristol Myers Squibb, Daiichi Sankyo, and Merck Sharp Dohme.

In 2023, Zymeworks advanced its pipeline and strengthened its collaborative model. A key highlight was the continued progress of zanidatamab, its lead HER2-targeted bispecific antibody. Zanidatamab is now in late-stage clinical development for several indications, including HER2-positive gastroesophageal adenocarcinoma and HER2-low breast cancer. The company also achieved milestones and maintained strong engagement across its diverse partnership portfolio, reinforcing the value of its technology platforms.

2. Financial Performance: Revenue, Profit, and Growth Metrics

Zymeworks reported total revenue of $78.5 million for fiscal year 2023, a notable increase from $62.1 million in 2022. Revenue primarily came from:

• Milestone Revenue: Payments received when partnered drug candidates achieve specific development goals, like advancing to new clinical trial phases.
• Research Support Payments: Funding from partners for Zymeworks' ongoing research and development.
• Drug Supply and Option Exercise Fees: Payments for providing drug candidates and for partners exercising licensing options.

Despite this revenue growth, Zymeworks posted a net loss of $182.3 million in 2023, an improvement from a $205.7 million net loss in 2022. This loss reflects the substantial investment necessary for drug development.

Key expenses included:

• Research and Development (R&D): $155.8 million in 2023 (down from $175.2 million in 2022), reflecting its core mission of discovering and advancing new therapies.
• General and Administrative (G&A): $52.1 million in 2023 (up from $48.5 million in 2022), covering operational costs, salaries, and corporate overhead.

The year-over-year reduction in net loss and R&D expenses indicates a more focused approach to pipeline development and cost management.

3. Major Wins and Challenges in 2023

Major Wins:

• Clinical Advancement of Zanidatamab: Zanidatamab, the lead candidate, advanced in pivotal clinical trials, with data readouts and regulatory interactions expected soon. This progress is a critical value driver for the company.
• Robust Partnership Activity: Zymeworks maintained and expanded collaborations with leading pharmaceutical companies, securing new milestone payments and research funding. This underscores the industry's confidence in its technology.
• Strategic Capital Raises: The company successfully raised capital, generating approximately $100 million in gross proceeds through an At-The-Market (ATM) financing facility and an additional $50 million from a private placement of common shares. These funds bolster its financial runway.
• Share Repurchase Program: In late 2023, Zymeworks' Board of Directors authorized a $50 million share repurchase program, signaling management's confidence in the company's valuation and commitment to shareholder value.

Challenges:

• Reliance on Partner Progress: Zymeworks' success heavily depends on its partners' ability to successfully develop, gain regulatory approval for, and commercialize drugs using Zymeworks' technology. Setbacks in partner programs directly impact Zymeworks.
• High Burn Rate: Despite cost management efforts, the company continues to incur significant R&D expenses, resulting in substantial net losses. Sustaining operations requires ongoing capital raises or eventual product commercialization.
• Intense Competition: The oncology and biotechnology sectors are highly competitive, with numerous companies vying for market share and clinical success in similar therapeutic areas.

4. Financial Health: Cash, Debt, and Liquidity

Zymeworks held $355.6 million in cash, cash equivalents, and marketable securities as of December 31, 2023. This strong liquidity position, even with its net loss, provides an estimated cash runway into late 2025. The capital raised through the ATM facility and private placement in 2023 significantly contributed to this healthy cash balance. The company carries no significant long-term debt. This financial strength is crucial for funding ongoing clinical trials and research.

5. Key Risks That Could Affect the Stock Price

• Clinical Trial Outcomes: The success of Zymeworks' drug candidates, especially zanidatamab, is paramount. Negative or inconclusive clinical trial results could significantly impact the stock price.
• Regulatory Approval Risk: Even successful clinical trials do not guarantee regulatory approval from agencies like the FDA; delays or rejections would be detrimental.
• Partner Dependence: A substantial portion of Zymeworks' potential future revenue relies on its partners' decisions, funding, and success. Agreement terminations or partner underperformance could severely impact Zymeworks.
• Intellectual Property Protection: Protecting its proprietary technology (Azymetric™, Zymelink™) and drug candidates from infringement is critical for Zymeworks' long-term value.
• Capital Requirements and Dilution: While currently well-capitalized, Zymeworks will likely need additional future funding to advance its pipeline. Such capital raises could dilute existing shareholders if not managed effectively.
• Competition: The highly competitive oncology market means Zymeworks' candidates must demonstrate superior efficacy or safety to gain market share.

6. Competitive Positioning

Zymeworks gains a competitive edge from its proprietary Azymetric™ and Zymelink™ technology platforms, which enable the creation of highly differentiated bispecific antibodies and ADCs. Its ability to attract and maintain collaborations with multiple top-tier pharmaceutical companies (Jazz, J&J, GSK, BMS, Daiichi Sankyo, Merck Sharp Dohme) strongly testifies to the perceived value and potential of its scientific approach and pipeline assets. Its lead candidate, zanidatamab, is positioned in the competitive HER2-targeted therapy space, aiming to address unmet needs in various cancer types.

7. Leadership and Strategy Changes

In 2023, Zymeworks maintained a stable leadership team, led by President and CEO Kenneth Galbraith. The company's strategic focus remained consistent, centered on four key pillars:

1. Advancing Lead Programs: Prioritizing the clinical development and potential commercialization of zanidatamab.
2. Leveraging Technology Platforms: Leveraging and innovating with Azymetric™ and Zymelink™ to generate new drug candidates.
3. Expanding and Maintaining Partnerships: Expanding and maintaining partnerships to drive non-dilutive funding and pipeline expansion.
4. Prudent Capital Allocation: Managing expenses efficiently and strategically deploying capital to extend its financial runway.

8. Future Outlook

Zymeworks' future outlook primarily centers on the continued clinical and regulatory progress of zanidatamab. Key anticipated events include:

• Top-line data readouts from pivotal trials for zanidatamab in HER2-positive gastroesophageal adenocarcinoma (expected late 2024/early 2025).
• Potential regulatory submissions for zanidatamab after successful trial results.
• Advancing earlier-stage pipeline candidates (e.g., ZW171, ZW191) into further clinical development.
• Executing the share repurchase program to enhance shareholder value.
• Evaluating new partnership opportunities to broaden its pipeline and secure additional funding.

The company aims to transition from a purely R&D-focused entity to one with commercialized products, either directly or through its partners, in the medium to long term.

9. Market Trends and Regulatory Changes Affecting Zymeworks

Zymeworks navigates the dynamic biotechnology and oncology markets, influenced by several key trends and factors:

• Growing Demand for Targeted Therapies: A growing understanding of cancer biology drives demand for highly specific treatments like bispecific antibodies and ADCs, aligning with Zymeworks' core focus.
• Regulatory Environment: The FDA and other global regulatory bodies adapt approval pathways for innovative oncology drugs, potentially offering expedited review for promising therapies addressing unmet medical needs. However, stringent safety and efficacy standards remain.
• Biologics Manufacturing Complexity: Developing and manufacturing complex biologics like antibodies present significant challenges and costs for Zymeworks.
• Competitive Landscape: Rapid innovation and intense competition characterize the oncology space, requiring Zymeworks to continuously demonstrate the differentiation and superiority of its candidates.
• Macroeconomic Factors: Broader economic conditions, interest rates, and investor sentiment towards the biotech sector can impact Zymeworks' ability to raise capital and its overall valuation.

Overall, Zymeworks shows promise with its proprietary technology platforms and lead candidate, zanidatamab, backed by strong partnerships and a healthy cash position. However, like any clinical-stage biotechnology company, its future hinges significantly on successful clinical trial outcomes and regulatory approvals. Weigh these factors carefully as you consider Zymeworks' potential.